Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a United States-based public company that is developing cannabinoid-based medicine and treatments focused on cancer and its side effects. Cannabics' approach can be used to develop cannabinoid-based therapies as preventive or primary cancer treatments – not just palliative, the way it's being used now. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move medical cannabinoids into the mainstream of cancer therapies. The company's R&D is based in Israel, where it is licensed to conduct scientific and clinical research on harnessing the therapeutic properties of cannabinoid formulations.